← All themes

Immunotherapy & Oncology

Cancer treatment has moved from poisoning dividing cells towards directing the immune system at the tumour, and towards drugs that carry their payload only to cancerous tissue. It absorbs more drug development spending than any other area.

388 stocks

#	Name	Funds holding	Growth	Growth %	Fund value
1	1 Johnson & Johnson JNJ $610B	3,674	-3	-0.1%	$323B
2	2 Pfizer PFE $169B	3,160	-35	-1%	$202B
3	3 Merck MRK $362B	3,015	+63	+2%	$172B
4	4 AbbVie ABBV $504B	3,006	-45	-1%	$187B
5	5 Bristol-Myers Squibb BMY $124B	2,540	+25	+1%	$127B
6	6 Amgen AMGN $237B	2,353	+17	+0.7%	$101B
7	7 Gilead Sciences GILD $197B	1,604	+5	+0.3%	$61.7B
8	8 Novartis NVS $287B	1,141	+4	+0.4%	$16.9B
9	9 Regeneron Pharmaceuticals REGN $82.5B	1,064	-31	-3%	$55B
10	10 AstraZeneca AZN $260B	1,016	+33	+3%	$35B
11	11 GSK GSK $98.7B	901	-29	-3%	$15.7B
12	SGEN 12 DELISTED Seagen Inc. Common Stock SGEN	548	+43	+9%	$29.1B
13	13 Incyte INCY $23B	537	+4	+0.8%	$16B
14	14 DELISTED Exact Sciences EXAS	501	-58	-10%	$6.56B
15	15 Jazz Pharmaceuticals JAZZ $13.9B	468	+6	+1%	$8.95B
16	16 Exelixis EXEL $15.6B	375	+12	+3%	$5.78B
17	17 Halozyme HALO $13.8B	368	+50	+16%	$5.65B
18	18 Guardant Health GH $22.5B	332	-24	-7%	$3.75B
19	19 Lantheus LNTH $6.53B	321	+45	+16%	$4.44B
20	20 BioNTech BNTX $22.8B	292	+5	+2%	$4.99B
21	21 Qiagen QGEN $9.59B	288	-5	-2%	$6.11B
22	22 Takeda Pharmaceutical TAK $62.6B	283	-5	-2%	$800M
23	23 Natera NTRA $58.6B	259	-27	-9%	$3.28B
24	24 NeoGenomics NEO $2.21B	239	-40	-14%	$956M
25	25 DELISTED Blueprint Medicines BPMC	237	-12	-5%	$3.19B